Adverse events ‐ hyperpigmentation ( · people with telangiectasias and reticular veins
Sclerotherapy (hypertonic saline) probably leads to lower adverse events ‐ hyperpigmentation ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
Adverse events ‐ matting ( · people with telangiectasias and reticular veins
Sclerotherapy (hypertonic saline) showed no clear difference in adverse events ‐ matting ( compared with sclerotherapy (any sclerosant) (moderate certainty).
1 finding from 1 review
Pain ( · people with telangiectasias and reticular veins
1 finding from 1 review
Recurrence · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to resolution · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life · people with telangiectasias and reticular veins
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Inadequate brain relaxation 3‐ or 4‐point scalesa · patients with brain relaxation undergoing craniotomy
Mannitol may leads to lower inadequate brain relaxation 3‐ or 4‐point scalesa compared with hypertonic saline (low certainty).
1 finding from 1 review
FEV1 · children with cystic fibrosis
Dornase alfa may leads to higher mean relative percentage in FEV1 (L) at 3 months compared with hypertonic saline (low certainty).
1 finding from 1 review
Mean relative percentage in FVC (L) at 3 months · children with cystic fibrosis
Dornase alfa showed no clear difference in mean relative percentage in FVC (L) at 3 months compared with hypertonic saline (low certainty).
1 finding from 1 review
Mean relative percentage in quality of life score at 3 months · children with cystic fibrosis
Dornase alfa showed no clear difference in mean relative percentage in quality of life score at 3 months compared with hypertonic saline (low certainty).
1 finding from 1 review
Pulmonary exacerbations · children with cystic fibrosis
1 finding from 1 review
Adverse events · children up to 12 months old with acute bronchiolitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Length of hospital stay · children up to 12 months old with acute bronchiolitis
It is very uncertain whether magnesium sulphate changes duration of hospital stay compared with hypertonic saline (very low certainty).
1 finding from 1 review
Clinical severity score (CSS) (RDAI score; range 0 to 17; higher = poorer outcomes) measured at 0 to 24 hoursafter treatment · children up to 12 months old with acute bronchiolitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical severity score (CSS) (RDAI score; range 0 to 17; higher = poorer outcomes) measured 25 to 48 hoursafter treatment · children up to 12 months old with acute bronchiolitis
It is very uncertain whether magnesium sulphate changes clinical severity score (CSS) (RDAI score; range 0 to 17; higher =… compared with hypertonic saline (very low certainty).
1 finding from 1 review
Hospital re‐admission within 30 days of discharge · children up to 12 months old with acute bronchiolitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Time to recovery · children up to 12 months old with acute bronchiolitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
All‐cause mortality · children up to 12 months old with acute bronchiolitis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
FEV1 % predicted · adults and children with cystic fibrosis
1 finding from 1 review
QoL · adults and children with cystic fibrosis
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found